NCT06309953View on ClinicalTrials.gov

A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

February 28, 2024

Primary Completion Date

June 17, 2024

Study Completion Date

June 17, 2024

Conditions
Dry Eye
Interventions
DRUG

Miebo

Miebo® (perfluorohexyloctane ophthalmic solution) Dosage: one drop of MIEBO four times daily into each eye Dosage form: Ophthalmic solution: 100% perfluorohexyloctane. Frequency: 4 times daily for 14 days

Trial Locations (7)

35233

Site 207, Birmingham

44141

Site 201, Brecksville

44145

Site 206, Westlake

55082

Site 204, Stillwater

64154

Site 202, Kansas City

66762

Site 203, Pittsburg

94954

Site 205, Petaluma

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY

NCT06309953 - A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease | Biotech Hunter | Biotech Hunter